{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:30Z","timestamp":1792242330806,"version":"4.4.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, four signal detection methods were applied to mine adverse drug events (ADEs) related to use of dual orexin receptor antagonists (DORAs) to provide reference for safe clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and Methods<\/jats:title>\n                    <jats:p>Data collected from Q3rd 2014 to Q4th 2023 were obtained from the FAERS database. According to the preferred terminology (PT) and systematic organ classification (SOC) of MedDRA v.26.0, the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN) were used to detect ADE signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11,857 DORAs-related adverse reactions were detected, reported with suvorexant, lemborexant, and daridorexant as the main suspected drugs was 8717584, and 2556, respectively. A higher proportion of females than males were reported (57.27% vs. 33.04%). The top 20 positive PT signals from three DORAs showed that \u201csleep paralysis\u201d ranked first. \u201cBrain fog\u201d was stronger following daridorexant but was not detected for the other two drugs, and \u201csleep sex\u201d and \u201cdyssomnia\u201d were stronger in suvorexant but not in the other two drugs. Additionally, some PTs occurred that were not included in drug instructions, such as \u201changover\u201d and \u201chypnagogic hallucination.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, four algorithms (ROR, PRR, BCPNN, and MGPS) were used to mine the safety signals of DORAs. We identified some potential ADE signals that can promote the rational use of DORAs and improve their safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1436405","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:48:35Z","timestamp":1722905315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Manxue","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingti","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"B1","first-page":"264","article-title":"Suvorexant, a dual orexin receptor antagonist for the management of insomnia","volume":"39","author":"Bennett","year":"2014","journal-title":"P T"},{"key":"B2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/brainsci13030480","article-title":"Impact of gender on insomnia","volume":"13","author":"Boer","year":"2023","journal-title":"Brain Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jsmc.2019.10.002","article-title":"Insomnia and cognitive performance","volume":"15","author":"Brownlow","year":"2020","journal-title":"Sleep. Med. Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40520-022-02310-w","article-title":"The impact of insomnia on frailty and the hallmarks of aging","volume":"35","author":"Carvalhas-Almeida","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cnur.2020.10.012","article-title":"Sleep and metabolic syndrome","volume":"56","author":"Chasens","year":"2021","journal-title":"Nurs. Clin. N. Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/ph17030342","article-title":"Safety of dual orexin receptor antagonist daridorexant: a disproportionality analysis of publicly available FAERS data","volume":"17","author":"Cicala","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.smrv.2020.101332","article-title":"Effects of orexin receptor antagonism on human sleep architecture: a systematic review","volume":"53","author":"Clark","year":"2020","journal-title":"Sleep. Med. Rev."},{"key":"B10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-319-23739-8_8","volume-title":"Hypnagogic hallucinations and sleep paralysis. Narcolepsy: a clinical guide","author":"D'Agostino","year":"2016"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e2022046","DOI":"10.23750\/abm.v93i2.11218","article-title":"Dream recall frequency and psychosomatics","volume":"93","author":"Dal Sacco","year":"2022","journal-title":"Acta Biomed. Atenei Parm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cger.2021.04.001","article-title":"Normal and abnormal sleep in the elderly","volume":"37","author":"Feinsilver","year":"2021","journal-title":"Clin. Geriatr. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"102047","DOI":"10.1016\/j.esmoop.2023.102047","article-title":"Insomnia in adult patients with cancer: ESMO clinical practice guideline","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"key":"B53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","article-title":"Quantitative methods in pharmacovigilance: focus on signal detection","volume":"26","author":"Hauben","year":"2003","journal-title":"Drug safety"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1339505","DOI":"10.3389\/fphar.2024.1339505","article-title":"Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database","volume":"15","author":"Hu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/0962280211430681","article-title":"Slope estimation for informatively right censored longitudinal data modelling the number of observations using geometric and Poisson distributions: application to renal transplant cohort","volume":"24","author":"Jaffa","year":"2015","journal-title":"Stat. Methods Med. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e008552","DOI":"10.1161\/JAHA.118.008552","article-title":"Self\u2010reported sleep duration and quality and cardiovascular disease and mortality: a dose\u2010response meta\u2010analysis","volume":"7","author":"Kwok","year":"2018","journal-title":"JAHA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1405023","DOI":"10.3389\/fphar.2024.1405023","article-title":"A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13311-021-01010-z","article-title":"Pharmacological management of insomnia","volume":"18","author":"Madari","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"zsad293","DOI":"10.1093\/sleep\/zsad293","article-title":"Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis","volume":"47","author":"Na","year":"2024","journal-title":"SLEEP"},{"key":"B23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.5664\/jcsm.4850","article-title":"Nightmares: under-reported, undetected, and therefore untreated","volume":"11","author":"Nadorff","year":"2015","journal-title":"J. Clin. Sleep. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.31887\/DCNS.2008.10.3\/dnutt","article-title":"Sleep disorders as core symptoms of depression","volume":"10","author":"Nutt","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40479-014-0023-4","article-title":"Nightmares affect the experience of sleep quality but not sleep architecture: an ambulatory polysomnographic study","volume":"2","author":"Paul","year":"2015","journal-title":"Borderline Personal. Disord. Emot. Dysregul."},{"key":"B26","doi-asserted-by":"publisher","first-page":"bcr2017222037","DOI":"10.1136\/bcr-2017-222037","article-title":"Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts","volume":"2017","author":"Petrous","year":"2017","journal-title":"BMJ Case Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/PRA.0000000000000672","article-title":"Comparative pharmacology of the 3 marketed dual orexin antagonists-daridorexant, lemborexant, and suvorexant: Part 1: pharmacokinetic profiles","volume":"28","author":"Preskorn","year":"2022","journal-title":"J. Psychiatr. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e14035","DOI":"10.1111\/jsr.14035","article-title":"The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J. Sleep. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"37400","DOI":"10.52965\/001c.37400","article-title":"Daridorexant for the treatment of insomnia","volume":"10","author":"Robinson","year":"2022","journal-title":"Health Psychol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1055\/s-0043-1768667","article-title":"Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis","volume":"81","author":"Rocha","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22nr03385","DOI":"10.4088\/PCC.22nr03385","article-title":"A 2023 update on managing insomnia in primary care: insights from an expert consensus group","volume":"25","author":"Rosenberg","year":"2023","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"23br14923","DOI":"10.4088\/JCP.23br14923","article-title":"Dual orexin receptor antagonists and suicide risk: findings from the WHO spontaneous reporting database","volume":"84","author":"Salvo","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/14740338.2019.1657091","article-title":"Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey","volume":"18","author":"Sano","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-0043-1770805","article-title":"Daridorexant, a recently approved dual orexin receptor antagonists (DORA) in treatment of insomnia","volume":"16","author":"Sarathi Chakraborty","year":"2023","journal-title":"Sleep. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"15","author":"Schutte-Rodin","year":"2008","journal-title":"J. Clin. Sleep. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","article-title":"Lemborexant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"896867","DOI":"10.3389\/fped.2022.896867","article-title":"Stevens-johnson syndrome following non-steroidal anti-inflammatory drugs: a real-world analysis of post-marketing surveillance data","volume":"10","author":"Shao","year":"2022","journal-title":"Front. Pediatr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s13311-020-00966-8","article-title":"Nightmare disorder and isolated sleep paralysis","volume":"18","author":"Stefani","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/jmh.jmh_18_22","article-title":"Menopause and sleep disorders","volume":"13","author":"Tandon","year":"2022","journal-title":"J. Mid-life Health"},{"key":"B42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/15402002.2016.1173551","article-title":"Where are the behavioral sleep medicine providers and where are they needed? A geographic assessment","volume":"14","author":"Thomas","year":"2016","journal-title":"Behav. Sleep. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/jcm10081660","article-title":"Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the us Food and drug administration adverse event reporting system (FAERS)","volume":"10","author":"Vestergaard Kvist","year":"2021","journal-title":"JCM"},{"key":"B45","doi-asserted-by":"publisher","first-page":"750458","DOI":"10.3389\/fnins.2021.750458","article-title":"Mapping the BCPNN learning rule to a memristor model","volume":"15","author":"Wang","year":"2021","journal-title":"Front. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11920-022-01357-w","article-title":"Orexin receptor antagonists and insomnia","volume":"24","author":"Wu","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1175372","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","article-title":"Suvorexant: first global approval","volume":"74","author":"Yang","year":"2014","journal-title":"Drugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"735466","DOI":"10.3389\/fcvm.2021.735466","article-title":"Cardiovascular toxicity of carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States","volume":"8","author":"Zhai","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1110575","DOI":"10.3389\/fphar.2023.1110575","article-title":"Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"766125","DOI":"10.3389\/fphar.2021.766125","article-title":"Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1436405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:48:39Z","timestamp":1722905319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1436405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":53,"alternative-id":["10.3389\/fphar.2024.1436405"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1436405","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"article-number":"1436405"}}